GHK-Cu

What GHK-Cu is and how it works

GHK is a tripeptide of glycine, histidine and lysine. Loren Pickart isolated it in 1973 from the albumin fraction of human plasma, while chasing a factor in serum that kept liver cells alive longer in culture. The peptide binds copper(II) tightly, and the copper complex, GHK-Cu, is the form most research uses.

The copper ion is held by nitrogen atoms from the glycine, the peptide backbone and the histidine ring. That arrangement underpins the oldest hypothesis about the molecule: that GHK acts as a shuttle, delivering copper where it is needed. Copper is a cofactor for repair enzymes, among them lysyl oxidase, which cross-links collagen and elastin. In cultured cells, GHK-Cu has also been linked to changes in the production of collagen, glycosaminoglycans and the enzymes that remodel the surrounding matrix.

Plasma levels of GHK are reported to fall with age, from roughly 200 ng/ml at 20 to roughly 80 ng/ml at 60. That decline is the starting point for most of the interest in the peptide, and it is a correlation. Nobody has shown that the lower level causes any feature of ageing, or that topping it up reverses one. In research terms GHK-Cu sits with the repair peptides, alongside BPC-157 and TB-500, though its proposed mechanism has little in common with either.

What the research on GHK-Cu shows

The laboratory case rests largely on fibroblasts. Maquart and colleagues reported in 1988 (FEBS Letters) that GHK-Cu stimulated collagen synthesis in fibroblast cultures at concentrations as low as one picomolar, with the largest effect near one nanomolar. A 1993 study from the same group in rats (Journal of Clinical Investigation) found more connective tissue accumulation in experimental wounds treated with GHK-Cu, while the copper-free peptide did nothing. That contrast matters: it suggests the metal is part of the activity rather than a passenger.

The widest claims concern gene expression. Using the Connectivity Map, a public database of expression profiles from human cell lines exposed to small molecules, a group led from Boston University reported in 2012 (Genome Medicine) that GHK reversed an expression pattern associated with emphysema, then showed that GHK restored the ability of lung fibroblasts from people with COPD to contract and remodel collagen in culture. Pickart and co-authors have since used similar analyses to argue that GHK shifts the activity of thousands of human genes towards a healthier pattern.

Those larger claims deserve a plain label. They rest on computational analysis of expression data, much of it generated by exposing cancer cell lines to compounds for a few hours. A pattern in that kind of data is a hypothesis, not a measured effect in a person.

The human evidence

Human data come almost entirely from topical use: small, short studies of creams and serums, with outcomes such as skin density, thickness and the appearance of fine lines. Those studies describe formulated cosmetics, not injected peptide. No large randomised trial has shown that GHK-Cu speeds wound healing or changes ageing skin in people.

GHK-Cu doses used in published research

These are exposures, not doses in the pharmacological sense. A concentration in a dish cannot be converted into an amount for an animal or a person, and the strength of a face cream says nothing about injection. No validated human dose exists for injected or oral GHK-Cu. The table records published study designs; it is not guidance for use in people.

GHK-Cu safety and side effects

Topical tolerability is reasonably well described. Almost everything else about GHK-Cu safety is unmeasured.

• On the skin. Copper tripeptide-1 has been formulated into skin care for decades and is generally regarded as well tolerated, with local irritation the usual complaint.
• By injection. There are no controlled human safety data. Tolerability, local reactions and the effects of repeated dosing have not been characterised in trials.
• Copper load. Copper accounts for roughly 16% of the complex by mass. It is an essential trace element that the body regulates tightly and that is toxic in excess, so any design involving repeated systemic dosing also delivers a copper dose.
• Research-grade material. A powder sold for laboratory work is not released under the rules that govern injectable medicines, including sterility and endotoxin testing.

Regulatory status of GHK-Cu in Europe

GHK-Cu is not a medicine in the EU and holds no marketing authorisation from the European Medicines Agency. In cosmetics it appears under the INCI name copper tripeptide-1, within the scope of Regulation (EC) No 1223/2009, which covers products applied to the external parts of the body, the teeth and the mucous membranes of the mouth. Injected or swallowed GHK-Cu falls outside that framework entirely, and anything presented as treating or preventing disease becomes a medicinal product requiring authorisation. Rules on possession and personal import differ between member states.

For athletes, the WADA Prohibited List bans under S0 any pharmacological substance without current approval for human therapeutic use. Cosmetic status is not therapeutic approval, so anyone in tested sport should ask their national anti-doping organisation before assuming that injectable research material is permitted.

Sourcing and quality of GHK-Cu

King Peptides stocks GHK-Cu 100 mg, and GHK-Cu is also one of four components in the KLOW-80 Blend - GHK-Cu + BPC-157 + TB-500 + KPV, where KPV is the tripeptide Lys-Pro-Val from the tail of alpha-MSH. The certificate of analysis should show HPLC purity of 99% or higher and a mass spectrum that matches the panel. Because the free peptide weighs 340.4 Da and the copper complex about 402 Da, the document should state which form it measured; a figure matching neither is a question for the supplier. A blend certificate should identify every component, not only the one in the product name. Our guide to reading a certificate of analysis covers the rest.

Orders are dispatched from the Netherlands, with a shop estimate of 1–2 business days within the Netherlands and 3–5 business days elsewhere in the EU and no customs formalities inside the union; parcels to the UK, Switzerland or Norway can be subject to import rules and duties. Packaging is neutral and tracked, and buyers confirm at checkout that they are 18 or older and ordering for research. The panel specifies storage at −20 °C in the dark, and our storage and reconstitution guide explains how to handle the vial on arrival.

GHK-Cu: frequently asked questions

Is research-grade GHK-Cu the same molecule as the copper peptide in skin creams? Yes. Copper tripeptide-1 is the cosmetic name for GHK-Cu. What differs is the product around it: a cream is a formulated cosmetic at a set concentration, the research vial unformulated powder for laboratory work.

Why is GHK-Cu blue? The colour comes from the copper(II) ion. Free GHK is a white powder, so material sold as GHK-Cu with no blue tint is worth querying with the supplier.

Does GHK-Cu reverse ageing? No study shows that. The fall in plasma levels with age is an observation, the gene-expression claims come from computational analysis, and the human evidence stops at topical studies.

How does GHK-Cu relate to epithalon? Both sit in the longevity corner of peptide research, but they are unrelated molecules with different proposed mechanisms: copper handling and matrix repair for GHK-Cu, telomerase for epithalon.